Aerie Pharmaceuticals Inc. (AERI)

23.42
NASDAQ : Health Technology
Prev Close 23.97
Day Low/High 23.29 / 24.38
52 Wk Low/High 20.72 / 64.25
Avg Volume 800.80K
Exchange NASDAQ
Shares Outstanding 45.94M
Market Cap 1.10B
EPS -5.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance And Provides Business Update

Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Announce Second Quarter 2019 Financial Results And Host Conference Call On Wednesday, August 7, 2019

Aerie Pharmaceuticals To Announce Second Quarter 2019 Financial Results And Host Conference Call On Wednesday, August 7, 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

First Week Of AERI September 20th Options Trading

First Week Of AERI September 20th Options Trading

Investors in Aerie Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AERI options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Aerie Pharmaceuticals Completes Enrollment Of The Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan Months Ahead Of Schedule

Aerie Pharmaceuticals Completes Enrollment Of The Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan Months Ahead Of Schedule

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals Announces Appointment Of Jeffrey Calabrese, CPA, As Director Of Accounting

Aerie Pharmaceuticals Announces Appointment Of Jeffrey Calabrese, CPA, As Director Of Accounting

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Present At Two Upcoming Investor Conferences

Aerie Pharmaceuticals To Present At Two Upcoming Investor Conferences

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Present At The Jefferies 2019 Healthcare Conference

Aerie Pharmaceuticals To Present At The Jefferies 2019 Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Business Update

Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility With Deerfield Management, Increasing Availability To $200M

Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility With Deerfield Management, Increasing Availability To $200M

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

Aerie Pharmaceuticals To Announce First Quarter 2019 Financial Results And Host Conference Call On Tuesday, May 7, 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For AR-13503 Sustained Release Implant

Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For AR-13503 Sustained Release Implant

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Is Now Oversold (AERI)

Aerie Pharmaceuticals Is Now Oversold (AERI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Risk and reward are the yin and yang of investing, and are closely related, especially in the pharmaceutical field.

Aerie Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference

Aerie Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Four Appointments

Aerie Pharmaceuticals Announces Four Appointments

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan Designed To Support Requirements For Future Regulatory Filing

Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan Designed To Support Requirements For Future Regulatory Filing

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial Of AR-1105 (Dexamethasone Intravitreal Implant) In Patients With Macular Edema Associated With Retinal Vein Occlusion

Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial Of AR-1105 (Dexamethasone Intravitreal Implant) In Patients With Macular Edema Associated With Retinal Vein Occlusion

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and...

Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue And Net Cash Burn Guidance

Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue And Net Cash Burn Guidance

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Present At Two Investor Conferences In March

Aerie Pharmaceuticals To Present At Two Investor Conferences In March

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance And Business Update

Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance And Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On Monday, February 25, 2019

Aerie Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On Monday, February 25, 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other...

Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For AR-1105 (Dexamethasone Intravitreal Implant)

Aerie Pharmaceuticals Announces Acceptance Of Its Investigational New Drug Application For AR-1105 (Dexamethasone Intravitreal Implant)

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other...

Aerie Pharmaceuticals Announces Positive Topline Results Of Netarsudil Ophthalmic Solution In Pilot Phase 2 Study Supporting Clinical Development In Japan

Aerie Pharmaceuticals Announces Positive Topline Results Of Netarsudil Ophthalmic Solution In Pilot Phase 2 Study Supporting Clinical Development In Japan

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other...

Aerie Pharmaceuticals Announces Appointment Of Ami Bavishi As Director, Investor Relations And Vincent Santucci, Pharm.D., As Director, Scientific Market Access

Aerie Pharmaceuticals Announces Appointment Of Ami Bavishi As Director, Investor Relations And Vincent Santucci, Pharm.D., As Director, Scientific Market Access

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other...

Interesting AERI Put And Call Options For August 2019

Interesting AERI Put And Call Options For August 2019

Investors in Aerie Pharmaceuticals Inc saw new options begin trading today, for the August 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Aerie Pharmaceuticals To Present At The Stifel 2018 Healthcare Conference

Aerie Pharmaceuticals To Present At The Stifel 2018 Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other...

Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Business Update

Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other...

Aerie Pharmaceuticals To Announce Third Quarter 2018 Financial Results And Host Conference Call On Tuesday, November 6, 2018

Aerie Pharmaceuticals To Announce Third Quarter 2018 Financial Results And Host Conference Call On Tuesday, November 6, 2018

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018.

TheStreet Quant Rating: D- (Sell)